Guizhou Sanli Pharmaceutical Co Ltd - Asset Resilience Ratio
Guizhou Sanli Pharmaceutical Co Ltd (603439) has an Asset Resilience Ratio of 2.10% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Guizhou Sanli Pharmaceutical Co Ltd working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2024)
This chart shows how Guizhou Sanli Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is Guizhou Sanli Pharmaceutical Co Ltd's balance sheet.
Liquid Assets Composition Over Time
This chart breaks down Guizhou Sanli Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Guizhou Sanli Pharmaceutical Co Ltd debt and liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥59.70 Million | 2.1% |
| Total Liquid Assets | CN¥59.70 Million | 2.10% |
Asset Resilience Insights
- Limited Liquidity: Guizhou Sanli Pharmaceutical Co Ltd maintains only 2.10% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Guizhou Sanli Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Guizhou Sanli Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Torrent Pharmaceuticals Limited
NSE:TORNTPHARM |
Drug Manufacturers - Specialty & Generic | 2.79% |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Beijing Tongrentang Co Ltd
SHG:600085 |
Drug Manufacturers - Specialty & Generic | 2.51% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Harbin Pharmaceutical Group Co Ltd
SHG:600664 |
Drug Manufacturers - Specialty & Generic | 0.97% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
Annual Asset Resilience Ratio for Guizhou Sanli Pharmaceutical Co Ltd (2021–2024)
The table below shows the annual Asset Resilience Ratio data for Guizhou Sanli Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.72% | CN¥22.95 Million ≈ $3.36 Million |
CN¥3.19 Billion ≈ $467.11 Million |
-1.04pp |
| 2023-12-31 | 1.76% | CN¥51.50 Million ≈ $7.54 Million |
CN¥2.92 Billion ≈ $427.35 Million |
-1.53pp |
| 2022-12-31 | 3.30% | CN¥59.91 Million ≈ $8.77 Million |
CN¥1.82 Billion ≈ $265.83 Million |
-3.68pp |
| 2021-12-31 | 6.98% | CN¥98.00 Million ≈ $14.34 Million |
CN¥1.40 Billion ≈ $205.59 Million |
-- |
About Guizhou Sanli Pharmaceutical Co Ltd
Guizhou Sanli Pharmaceutical Co.,Ltd, together with its subsidiaries, engages in the plantation, research, development, production, and sale of pharmaceutical products in China. The company offers respiratory system, tonic, gynecological, and orthopedic medications, as well as cardiovascular and cerebrovascular drugs, and other medicines. It also provides products in various dosage forms, includi… Read more